Stay in touch
We'd love to keep in touch about news, events and how you can get involved. To hear from us, please sign up below.
We’re here, working with the brightest minds in labs across the UK and Ireland, making life-saving breast cancer research happen.
Drugs that help the immune system to detect and destroy cancer cells show promise as a treatment for triple negative breast cancer. Dr Anne Armstrong will be running a trial to see whether giving aspirin alongside one of these drugs makes the treatment more effective at controlling tumours.
Palbociclib is a drug given to people with secondary, oestrogen receptor positive (ER+) breast cancer to help manage their disease. Dr Saskia Wilting is trying to find out who will benefit from taking this drug and why some cancers do not respond to it.
Lobular breast cancer can be more difficult to treat than some other types of breast cancer. Dr Patrick Derksen is looking at whether combinations of palbociclib and gedatolisib could stop this type of breast cancer progressing, giving women the best possible chance of survival.
Professor Simak Ali and Dr Lesley-Ann Martin are investigating how proteins called CDKs play a part in cancer’s resistance to palbociclib – a drug used to treat oestrogen receptor positive (ER+) secondary breast cancer. He is exploring whether blocking a protein called CDK7 could be a new way to treat tumours that have become resistant to palbociclib.
Professor Jukka Westermarck is finding new ways to predict which existing drugs will be most effective for triple negative breast cancers. He is investigating how different combinations of altered proteins in cancer cells affect their response to a number of experimental drugs.
Professor Catrin Pritchard and her team has developed a new, more personalised type of tumour model to test drugs before they enter clinical trials. She is exploring whether this system can more accurately represent how drugs will work when given to patients.